Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel plus pegvisomant in acromegaly uncontrolled on lanreotide
2006-000297-72Phase 3Completed
- Sponsor
- Ipsen
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanreotide and pegvisomant in acromegaly, sponsored by Ipsen. Primary endpoint: Normalized IGF-1 at end of co-treatment period. Started Sep 2006; status: completed.
02
Drugs
lanreotidepegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2006-000297-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000297-72.